Published:
Category: Publications

CCTG CO26: A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study

Read More

Published:
Category: Publications
Supplementary publications for the CCTG PR7 study. Read More

Published:
Category: Publications
Practice changing OlympiA (CCTG MA36) trial results
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine. Read More

Published:
Category: Publications
ASCO 2021 - CCTG Poster Sessions
CCTG trials with poster presentations at ASCO 2021 including, CCTG CRC2 (NCCTG N0147), CCTG CO28, CCTG CRC9 (NRG GI-005), CCTG PA7, CCTG REC4 (ECOG-ACRIN 8143). Read More

Published:
Category: Publications

CCTG CE8 | EORTC 1709: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Read More



Published:
Category: Group updates

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:

Read More

Published:
Category: Group updates
A new career opportunity is available at the CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario. Read More

Published:
Category: Group updates